Bruno Azevedo Randi, Hermes Ryoiti Higashino, Vinícius Ponzio da Silva, Matias Chiarastelli Salomão, Antonio Carlos Campos Pignatari, Edson Abdala, Fabiana Vasques, Celso Arrais Rodrigues da Silva, Roberto Luiz da Silva, Carolina Dos Santos Lazari, José Eduardo Levi, Erick Menezes Xavier, Marina Farrel Côrtes, Alessandra Luna-Muschi, Vanderson Rocha, Silvia Figueiredo Costa
Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51...
2024: Revista do Instituto de Medicina Tropical de São Paulo